Investing.com - Axsome Therapeutics (NASDAQ:AXSM) Inc reported on Monday third quarter earnings that beat analysts' forecasts and revenue that topped expectations. Axsome...
Investing in mid-cap stocks is essential for investors who prefer a diversified portfolio. These stocks offer a middle ground with regard to the risks and rewards when compared to...
Axsome Therapeutics (NASDAQ:AXSM), Inc. AXSM has been struggling lately, but the selling pressure may be coming to an end soon. That is because AXSM recently saw a Hammer Chart...
Axsome Therapeutics (NASDAQ:AXSM), Inc. AXSM announced that it plans to submit a new drug application (NDA) for its pipeline candidate, AXS-14, in the fourth quarter of 2022. The...
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
|Average||108.87 (+53.68% Upside)|
|No. of Analysts||15|